MGC Pharmaceuticals Ltd
ASX:MXC
MGC Pharmaceuticals Ltd
ASX:MXC
Price:
0.415
AUD
Market Cap:
AU$18.2m
Relative Value
There is not enough data to reliably calculate the relative value of MXC.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MXC
Relative Value
Base Case
Not Available
Multiples Across Competitors
MXC Competitors Multiples
MGC Pharmaceuticals Ltd Competitors
MGC Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
MGC Pharmaceuticals Ltd
ASX:MXC
|
18.2m AUD | 13.7 | -1.1 | -0.8 | -0.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
924.3B USD | 14.2 | 44.8 | 30.2 | 32.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
575.3B USD | 6.1 | 21.5 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.3B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
240.6B CHF | 5.5 | 22.1 | 13.7 | 17.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
230.1B GBP | 5.3 | 30.2 | 16.7 | 23.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.9B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.3B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD | 2.5 | 17.3 | 7.3 | 9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
